- Firebrick’s core patent covering Nasodine® Nasal Spray as a treatment for the common cold will now be granted in 28 countries
Firebrick Pharma Limited (ASX:FRE) is pleased to announce that its core patent covering Nasodine® Nasal Spray as a treatment and preventative for the common cold has now been allowed in Canada.
Once this proceeds to grant, it will bring the number of countries where this patent has been granted to 28, now covering North America, Europe, Australia and other key markets (see announcement 25 October 2022 for list of countries).
The core Nasodine patent is titled: “Treatment and prevention of the common cold using povidone-iodine,” and protects the intranasal use of povidone-iodine (in any form) for the treatment or prevention of the common cold.
The patent expires in most countries in 2035 and in Australia, in 2034. Granted claims generally include treating and preventing colds, reducing the viral load of common cold viruses, prevention of secondary complications of colds, and reducing the risk of serious complications in at-risk populations.
With the allowance of the Canadian patent and the recent withdrawal of the pending Japanese patent application, this patent is no longer pending in any country.
In addition, Firebrick has two other patents pending in most countries, including the use of Nasodine for prevention of pandemic viral diseases, and a pharmaceutical formulation patent application that covers the specific Nasodine formulation.